RAPT Therapeutics shares surge 64% as GSK agrees $2.2B acquisition
Shares of RAPT Therapeutics surged sharply on Tuesday after the biopharmaceutical company said it had agreed to be acquired by British drugmaker GSK in a deal valued at about $2.2 billion, giving the larger group access to a late-stage food allergy treatment. RAPT stock jumped 64% to $57.41 in premarket trading, approaching the agreed offer
